Clinical Trial

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometriosis-related cancer. The name of the study drug involved in this study is: \- Belzutifan (a type of Hypoxia-Inducible Factor-2 alpha (HIF-2a) inhibitor)
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-11-05; most recent amendment 2025-11-03.
Status change: Not Yet Recruiting → Recruiting 2025-01-10
Trial Details
NCT Number NCT06677190
Lead Sponsor Dana-Farber Cancer Institute
Collaborators: Merck Sharp & Dohme LLC
Conditions Ovarian Cancer, Ovarian Carcinoma, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Vulvar Cancer, Gynecologic Cancer, Vaginal Cancer
Enrollment 32 participants
Start Date 2024-12-20
Primary Completion 2026-12-30 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-05